Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03145558 · ClinicalTrials.gov registry record · Phase 2
TATE Versus TACE in Intermediate Stage HCC
A Phase 2 study, sponsored by Teclison.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT03145558: Clinical Trial Phase 2 study, sponsored by Teclison.
NCT03145558 is a Phase 2 study that was terminated before completion, run by Teclison. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03145558, a Phase 2 study, was terminated before completion, sponsored by Teclison.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
An open label randomized study to compare TATE versus TACE in patients with intermediate stage Hepatocellular carcinoma who are not suitable for surgical resection or radiofrequency ablation. The primary endpoint is Progression Free Survival. Secondary endpoints including CR rate, Time to embolization failure, Duration of CR, OS, ORR, local control rate, time to local recurrence and duration to local recurrence. The study treatment is to compare Tirapazamine versus doxorubicin when combined with trans-arterial embolization. Study plans to enroll 134 patients in 1:1 randomization for TATE or TACE. MRI will be used to assess efficacy using a central radiological review for the final analysis.
Primary Outcome
mRECIST criteria
Interventions
- DRUG Doxorubicin
- DRUG Tirapazamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2017-12-05 |
| Est. Completion | 2024-06-30 |
| Phase | Phase 2 |
Why NCT03145558 stopped before completion
NCT03145558 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Doxorubicin is the first listed.
NCT03145558 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03145558 about?
NCT03145558 is a clinical study titled "TATE Versus TACE in Intermediate Stage HCC". An open label randomized study to compare TATE versus TACE in patients with intermediate stage Hepatocellular carcinoma who are not suitable for surgical resection or radiofrequency ablation. The primary endpoint is Progression Free Survival. Secondary endpoints including CR rate, Time to embolizati...
What is the current status of trial NCT03145558?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2017-12-05. Estimated completion is 2024-06-30.
What interventions are being tested in trial NCT03145558?
The interventions under investigation include: Doxorubicin (DRUG), Tirapazamine (DRUG).
Who is sponsoring clinical trial NCT03145558?
This trial is sponsored by Teclison, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03145558's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI